Edition:
United Kingdom

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

4.15USD
22 May 2018
Change (% chg)

$-0.03 (-0.60%)
Prev Close
$4.18
Open
$4.20
Day's High
$4.20
Day's Low
$4.15
Volume
3,665
Avg. Vol
56,374
52-wk High
$13.00
52-wk Low
$2.80

Latest Key Developments (Source: Significant Developments)

Immune Design Reports Q4 Loss Per Share $0.29
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Immune Design Corp ::IMMUNE DESIGN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.29.Q4 REVENUE $500,000.Q4 REVENUE VIEW $1 MILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.IMMUNE DESIGN - EXPECTS TO HAVE CASH TO FUND OPERATIONS INTO H2 2020.  Full Article

Ecor1 Capital reports 7.4% passive stake in Immune Design
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Ecor1 Capital Llc::Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​.  Full Article

Immune Design reports Q3 loss per share of $0.52
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Immune Design Corp -:IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.52.Q3 REVENUE $500,000.Q3 REVENUE VIEW $1.4 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.  Full Article

Immune Design prices offering of 19.5 million shares at $4.10 per share​
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Immune Design Corp :Immune Design prices $80.0 million public offering of common stock.Says ‍priced public offering of 19.5 million shares of its common stock at price to public of $4.10 per share​.  Full Article

Immune Design proposes public offering of common stock
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Immune Design Corp :Immune Design announces proposed public offering of common stock.Immune Design Corp - ‍plans to offer and sell up to 16 million shares of its common stock in an underwritten public offering​.Immune Design Corp - ‍net proceeds of offering to fund its Phase 3 clinical trial for CMB305 in synovial sarcoma patients & to continue to develop CA21.  Full Article

Immune Design gets positive FDA feedback on Phase 3 clinical trial design for CMB305
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Immune Design Corp :Immune Design announces positive FDA feedback on Phase 3 clinical trial design for CMB305 in synovial sarcoma patients.Immune Design- plans to initiate pivotal Phase 3 trial to support a Biologics License Application (BLA) for CMB305 in patients with synovial sarcoma​.  Full Article

Immune Design Q2 loss per share $0.54
Wednesday, 2 Aug 2017 

Aug 2 (Reuters) - Immune Design Corp :Immune Design reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.54.Q2 revenue $700,000.Q2 revenue view $1.8 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Immune Design Corp - ‍based on current expectations, co continues to expect to have cash to fund operations into second half of 2018​.  Full Article

Immune Design Q1 loss per share $0.50
Wednesday, 17 May 2017 

May 17 (Reuters) - Immune Design Corp ::Immune Design reports first quarter 2017 financial results and provides corporate update.Q1 loss per share $0.50.Q1 revenue $5.5 million.Q1 revenue view $2.1 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S.  Full Article

Immune Design Q4 loss per share $0.57
Tuesday, 7 Mar 2017 

Immune Design Corp : Immune design reports fourth quarter and full year 2016 financial results and provides corporate update . Q4 loss per share $0.57 . Q4 revenue $2.1 million . Q4 revenue view $1.6 million -- Thomson Reuters I/B/E/S .Q4 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

BRIEF-Immune Design Q1 Loss Per Share $0.28

* IMMUNE DESIGN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE